NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market on Wednesday that its fourth quarter revenues rose 123 percent, thanks largely to an increase in its average revenue per test, year over year.

The company reported Q4 revenues of $805,000, up from $361,000 in Q4 2015.

Vermillion posted $680,000 in product revenues from sales of its OVA1 ovarian cancer test, and $125,000 in service revenue from its Aspira IVD business. All of Vermillion's revenues in Q4 2015 came from OVA1 sales.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.